Catalyst Pharmaceuticals (CPRX) Profit After Tax (2010 - 2026)

Catalyst Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at $63.7 million for Q1 2026.

• Quarterly Profit After Tax rose 12.51% year-over-year to $63.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.3 million (up 12.18% YoY) and the FY2025 annual result came in at $214.3 million, up 30.78% from the prior year.
• Profit After Tax was $63.7 million for Q1 2026 at Catalyst Pharmaceuticals, up from $52.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at $63.7 million in Q1 2026 and bottomed at -$30.8 million in Q3 2023.
• A 5-year average of $35.1 million and a median of $37.8 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 235.26% — and 2024, when it surged 242.63%.
• Catalyst Pharmaceuticals' Profit After Tax stood at $25.5 million in 2022, then surged by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025, then rose by 20.96% to $63.7 million in 2026.
• Business Quant data shows CPRX's Profit After Tax at $63.7 million in Q1 2026, $52.7 million in Q4 2025, and $52.8 million in Q3 2025.